Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05775159
What this trial is testing

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Who this might be right for
Hepatocellular CarcinomaBiliary Tract Cancer
AstraZeneca 294
Early research (Phase 1)Study completedNCT04501770
What this trial is testing

M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors

Who this might be right for
HER2-Positive Solid Tumors
Wuhan YZY Biopharma Co., Ltd. 34
Not applicableWithdrawnNCT06769555
What this trial is testing

BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

Who this might be right for
AL Amyloidosis
Institute of Hematology & Blood Diseases Hospital, China
Testing effectiveness (Phase 2)Looking for participantsNCT07641023
What this trial is testing

Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC

Who this might be right for
Non-Small Cell Lung CancerAdvanced/Metastatic
Beijing Biotech 60
Testing effectiveness (Phase 2)Ended earlyNCT03983395
What this trial is testing

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Ichnos Sciences SA 1
Testing effectiveness (Phase 2)Study completedNCT05773105
What this trial is testing

Cadonilimab Combined With Regorafenib in Patients With Advanced HCC

Who this might be right for
Advanced Hepatocellular Carcinoma
Sun Yat-sen University 36
Testing effectiveness (Phase 2)Study completedNCT01221675
What this trial is testing

TF2- Small Cell Lung Cancer Radio Immunotherapy

Who this might be right for
Small Cell Lung CancerCEA-expressing Non Small Cell Lung Carcinoma (NSCLC)
Centre René Gauducheau 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06586294
What this trial is testing

Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 294
Testing effectiveness (Phase 2)UnknownNCT05930665
What this trial is testing

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Who this might be right for
Pleural Mesothelioma
Sun Yat-sen University 38
Testing effectiveness (Phase 2)Ended earlyNCT04631601
What this trial is testing

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Amgen 55
Testing effectiveness (Phase 2)Looking for participantsNCT07255404
What this trial is testing

A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)
BioNTech SE 105
Large-scale testing (Phase 3)Active Not RecruitingNCT06230224
What this trial is testing

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals 216
Testing effectiveness (Phase 2)Looking for participantsNCT07432022
What this trial is testing

A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Combination TherapyAggressive B-Cell Non-Hodgkin LymphomaEMB07+1 more
Shanghai EpimAb Biotherapeutics Co., Ltd. 115
Early research (Phase 1)Looking for participantsNCT06166888
What this trial is testing

AK131 in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Akeso 130
Testing effectiveness (Phase 2)Looking for participantsNCT07652905
What this trial is testing

CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

Who this might be right for
Plasma Cell Leukemia (PCL)
Institute of Hematology & Blood Diseases Hospital, China 24
Early research (Phase 1)Study completedNCT04047290
What this trial is testing

AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Who this might be right for
Neoplasms Malignant
Akesobio Australia Pty Ltd 80
Testing effectiveness (Phase 2)Looking for participantsNCT06951646
What this trial is testing

CtDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Who this might be right for
Non Small Cell Lung CancerImmune Checkpoint Inhibitors (ICIs)
Second Xiangya Hospital of Central South University 70
Testing effectiveness (Phase 2)Study completedNCT05214482
What this trial is testing

AK112 in Advanced Malignant Tumors

Who this might be right for
Advanced Malignant Tumors
Akeso 154
Testing effectiveness (Phase 2)Study completedNCT05505825
What this trial is testing

AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

Who this might be right for
SCLC,Extensive Stage
Akeso 36
Testing effectiveness (Phase 2)Ended earlyNCT00452140
What this trial is testing

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Neovii Biotech 40
Next Page